Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology enterprise creating cell therapies for a huge array of autoimmune ailments, announces nowadays it has appointed Prof. Daniel Shelly, PhD, MBA, into the part of Main Organization Development Officer, to enable PolTREG create the strategic, business, analysis and pharmaceutical partnerships that will permit the enterprise to productively commercialise its robust pipeline of cell therapies for ailments these kinds of as Variety-1 Diabetes (T1D), A number of Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).
“I am elated we have been ready to appeal to Dan to support us produce the guarantee of Treg cell therapies for a wide selection of autoimmune diseases. PolTREG has the most detailed pipeline of cell therapies for autoimmune illnesses, such as Variety-1 Diabetic issues and Numerous Sclerosis, and Dan’s arrival will help us to carry on to provide the milestones that will carry our direct property nearer to market place,” claimed Prof. Piotr Trzonkowski, Chief Govt Officer of PolTREG.
Dr Shelly is an astute veteran of the existence science industry, with a deep comprehending of biology and the Treg cell therapies that PolTREG is acquiring. He has a proven monitor history of closing business advancement promotions for a extensive range of biotech organizations, which includes most a short while ago many early-stage analysis deals for Prescient Therapeutics Ltd., a clinical phase oncology organization building personalised drugs methods to cancer, making use of Motor vehicle-T systems. He was Director of World-wide Business enterprise Advancement and Strategic Partnerships for the world wide non-gain Route, wherever he was the Co-Direct for the COVID-19 process drive. He is an adjunct associate professor at the University of Cincinnati, in which he teaches biologics discovery, pharmaco-economics and biotech small business, publishes in scientific journals, and is a regularly invited speaker and considered leader at global cell therapy conferences. Dr Shelly has a in depth comprehension of the clinical development pathway, with immediate working experience of regulatory submissions, and is competent in clinical asset valuation and due diligence.
PolTREG offers the most advanced pipeline for Treg cell therapies in autoimmune disorder, with its direct prospect, PTG-007, in mid-phase medical experiments in T1D and MS. In addition, the corporation expects to start off To start with-in-Human clinical trials of its Automobile-Tregs for two neurodegenerative conditions – MS and ALS – in early 2025.
Complementing PolTREG’s modern scientific pipeline is the new opening of one particular of Europe’s largest CGMP mobile treatment production services. The facility, one of the most sophisticated of its variety, will have about 2,100 sqm of laboratory house, together with 15 operational manufacturing traces, a ability that can be appreciably further more expanded. The facility currently can provide daily life-bettering cell therapies any where in Europe in 24 hours post generation.
PolTREG was the first corporation in the planet to administer Treg therapies to sufferers and the very first to commence receiving revenues from its direct product. So significantly, PolTREG has properly treated 27 patients with PTG-007 commercially less than a hospital exemption software in Poland.
About PolTREG
PolTREG is a world wide leader in creating autoimmune therapies centered on T-regulatory cells (Tregs). Its lead solution, PTG-007, autologous Treg cure for early-onset Form-1 Diabetes (T1D) is ready for Period 2/3 clinical testing, for which the organization is searching for a partnership. The business will start Stage 2 trials for PTG-007 to handle Various Sclerosis (MS) in the second 50 percent of 2024, for RRMS and PPMS. PolTREG also has engineered Tregs, like Car-Tregs, antigen-distinct Tregs and TCR-Tregs, in the preclinical phase. PolTREG has concluded four scientific trials with additional than 100 sufferers dealt with with Tregs.
For extra information and facts make sure you check out www.poltreg.com.
For even further data make sure you speak to:
| PolTREG S.A. Prof Piotr Trzonkowski Chief Government Officer [email protected] +48 512 532 401 |
Investor Relations Chris Maggos Cohesion Bureau +41 79 367 62 54 [email protected] Media Relations |
Essential facts
The contents of this announcement incorporate statements that are, or may well be deemed to be, “ahead-on the lookout statements”. These ahead-on the lookout statements can be recognized by the use of ahead-searching terminology, such as the words “thinks”, “estimates,” “anticipates”, “expects”, “intends”, “might”, “will”, “plans”, “carry on”, “ongoing”, “probable”, “forecast”, “task”, “target”, “seek” or “ought to”, and incorporate statements the Corporation makes about the meant effects of its method. By their nature, forward-hunting statements involve risks and uncertainties and audience are cautioned that any these ahead-searching statements are not ensures of future functionality. The company’s real benefits may possibly differ materially from all those predicted by the ahead-wanting statements. The enterprise undertakes no obligation to publicly update or revise forward-wanting statements, besides as may possibly be demanded by regulation.
- 20240216 PolTREG PR Dan Shelly – accepted
- Daniel Shelly
